open access

Ahead of print
Original paper
Published online: 2024-03-13
Get Citation

Cystatin C improves cardiovascular risk prediction in cardiometabolic patients in addition to estimated glomerular filtration rate

Inna Pavlivna Dunaieva1
Affiliations
  1. Department of Clinical Pharmacology and Internal Medicine, Kharkiv National Medical University, Kharkiv, Ukraine

open access

Ahead of print
ORIGINAL PAPERS
Published online: 2024-03-13

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

Cystatin C; cardiovascular disease; glomerular filtration rate

About this article
Title

Cystatin C improves cardiovascular risk prediction in cardiometabolic patients in addition to estimated glomerular filtration rate

Journal

Arterial Hypertension

Issue

Ahead of print

Article type

Original paper

Published online

2024-03-13

Page views

13

Article views/downloads

7

Keywords

Cystatin C
cardiovascular disease
glomerular filtration rate

Authors

Inna Pavlivna Dunaieva

References (12)
  1. Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015; 24(3): 295–300.
  2. Krstic D, Tomic N, Radosavljevic B, et al. Biochemical Markers of Renal Function. Curr Med Chem. 2016; 23(19): 2018–2040.
  3. Levey AS, Fan Li, Eckfeldt JH, et al. Cystatin C for glomerular filtration rate estimation: coming of age. Clin Chem. 2014; 60(7): 916–919.
  4. Onopiuk A, Tokarzewicz A, Gorodkiewicz E. Cystatin C: a kidney function biomarker. Adv Clin Chem. 2015; 68: 57–69.
  5. Carvalho LS, Silva TQ, Coelho-Filho OR. Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality. Arq Bras Cardiol. 2018; 111(6): 808–809.
  6. Magnusson M, Molvin J, Engström G, et al. Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses. PLoS One. 2016; 11(5): e0155735.
  7. van der Laan SW, Fall T, Soumaré A, et al. Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study. J Am Coll Cardiol. 2016; 68(9): 934–945.
  8. Luo J, Wang LP, Hu HF, et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis. Clin Chim Acta. 2015; 450: 39–45.
  9. Xu Y, Ding Y, Li X, et al. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol Cell Biol. 2015; 93(5): 442–451.
  10. Satoh-Asahara N, Suganami T, Majima T, et al. Japan Obesity and Metabolic Syndrome Study (JOMS) Group. Urinary cystatin C as a potential risk marker for cardiovascular disease and chronic kidney disease in patients with obesity and metabolic syndrome. Clin J Am Soc Nephrol. 2011; 6(2): 265–273.
  11. Dejenie TA, Abebe EC, Mengstie MA, et al. Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14: 1124367.
  12. Dedual MA, Wueest S, Challa TD, et al. Obesity-Induced Increase in Cystatin C Alleviates Tissue Inflammation. Diabetes. 2020; 69(9): 1927–1935.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl